160 related articles for article (PubMed ID: 38072134)
1. Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
[TBL] [Abstract][Full Text] [Related]
2. Polycomb repressive complex's evolutionary conserved function: the role of EZH2 status and cellular background.
Gall Trošelj K; Novak Kujundzic R; Ugarkovic D
Clin Epigenetics; 2016; 8():55. PubMed ID: 27239242
[TBL] [Abstract][Full Text] [Related]
3. Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation.
Bamidele AO; Svingen PA; Sagstetter MR; Sarmento OF; Gonzalez M; Braga Neto MB; Kugathasan S; Lomberk G; Urrutia RA; Faubion WA
Cell Mol Gastroenterol Hepatol; 2019; 7(1):55-71. PubMed ID: 30510991
[TBL] [Abstract][Full Text] [Related]
4. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
Cheng Y; Song Z; Fang X; Tang Z
Clin Epigenetics; 2024 Apr; 16(1):54. PubMed ID: 38600608
[TBL] [Abstract][Full Text] [Related]
5. Point mutations in the WD40 domain of Eed block its interaction with Ezh2.
Denisenko O; Shnyreva M; Suzuki H; Bomsztyk K
Mol Cell Biol; 1998 Oct; 18(10):5634-42. PubMed ID: 9742080
[TBL] [Abstract][Full Text] [Related]
6. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
[TBL] [Abstract][Full Text] [Related]
7. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
8. Unlocking adult T-cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1/2 inhibition.
Tavakoli Shirazi P; Bywater MJ
Immunol Cell Biol; 2024; 102(5):298-301. PubMed ID: 38606590
[TBL] [Abstract][Full Text] [Related]
9. EZH2 in Myeloid Malignancies.
Rinke J; Chase A; Cross NCP; Hochhaus A; Ernst T
Cells; 2020 Jul; 9(7):. PubMed ID: 32650416
[TBL] [Abstract][Full Text] [Related]
10. Role of EZH2 in adipogenesis and obesity: Current state of the art and implications - A review.
Wang H
Medicine (Baltimore); 2022 Sep; 101(36):e30344. PubMed ID: 36086687
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of
Demosthenous C; Gupta SK; Sun J; Wang Y; Troska TP; Gupta M
Front Oncol; 2020; 10():1226. PubMed ID: 32850364
[TBL] [Abstract][Full Text] [Related]
12. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.
Mochizuki-Kashio M; Aoyama K; Sashida G; Oshima M; Tomioka T; Muto T; Wang C; Iwama A
Blood; 2015 Sep; 126(10):1172-83. PubMed ID: 26219303
[TBL] [Abstract][Full Text] [Related]
13.
León TE; Rapoz-D'Silva T; Bertoli C; Rahman S; Magnussen M; Philip B; Farah N; Richardson SE; Ahrabi S; Guerra-Assunção JA; Gupta R; Nacheva EP; Henderson S; Herrero J; Linch DC; de Bruin RAM; Mansour MR
Cancer Discov; 2020 Jul; 10(7):998-1017. PubMed ID: 32349972
[TBL] [Abstract][Full Text] [Related]
14. EZH2 as a mediator of treatment resistance in melanoma.
Tiffen JC; Gallagher SJ; Tseng HY; Filipp FV; Fazekas de St. Groth B; Hersey P
Pigment Cell Melanoma Res; 2016 Sep; 29(5):500-7. PubMed ID: 27063195
[TBL] [Abstract][Full Text] [Related]
15. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
Bao Q; Kumar A; Wu D; Zhou J
Drug Discov Today; 2024 Jun; 29(6):103986. PubMed ID: 38642703
[TBL] [Abstract][Full Text] [Related]
16. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.
Kaito S; Iwama A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374737
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
19. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
20. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
